Literature DB >> 17530296

Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS.

Lawrence Copelovitch1, Marta Guttenberg, Martin R Pollak, Bernard S Kaplan.   

Abstract

Familial and genetic forms of focal segmental glomerulosclerosis (FSGS) are associated with six different mutations in genes affecting the podocyte (NPHS2, ACTN4, CD2AP, WT1, TRPC6, and PLCE1). Immunosuppressive agents are often unsuccessful in treating this condition. Data regarding the efficacy of renoprotection through blockage of the renin-angiotensin axis is lacking. We describe three children from two different families with familial FSGS in whom partial to complete remission of proteinuria was attained through early blockade of the renin-angiotensin axis. In addition, there was no deterioration of renal function. We speculate that presymptomatic patients with normal renal function who have genetic or familial FSGS may benefit from early blockade of the renin-angiotensin axis and that this may also prevent progressive renal disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530296     DOI: 10.1007/s00467-007-0505-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

Review 1.  Is regression of chronic nephropathies a therapeutic target?

Authors:  Giuseppe Remuzzi; Andrea Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-03-16       Impact factor: 10.121

2.  Focal segmental glomerulosclerosis--does treatment work?

Authors:  C M Stirling
Journal:  Nephron Clin Pract       Date:  2006-06-19

3.  Genetic testing comes of age: WT1 mutations in steroid-resistant nephrotic syndrome: commentary on the article by Mucha et al. on page 325.

Authors:  Thomas Benzing
Journal:  Pediatr Res       Date:  2006-02       Impact factor: 3.756

4.  Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.

Authors:  Li-Jun Ma; Shinya Nakamura; Jean Claude Aldigier; Michele Rossini; Haichun Yang; Xiubin Liang; Ikuko Nakamura; Carmelita Marcantoni; Agnes B Fogo
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

5.  Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention.

Authors:  Daniela Macconi; Mauro Abbate; Marina Morigi; Stefania Angioletti; Marilena Mister; Simona Buelli; Maria Bonomelli; Peter Mundel; Karlhans Endlich; Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

6.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

Review 7.  Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis.

Authors:  Stephen M Korbet
Journal:  Semin Nephrol       Date:  2003-03       Impact factor: 5.299

8.  Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.

Authors:  M Usta; A Ersoy; K Dilek; B Ozdemir; M Yavuz; M Güllülü; M Yurtkuran
Journal:  J Intern Med       Date:  2003-03       Impact factor: 8.989

9.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

Authors:  Rainer G Ruf; Anne Lichtenberger; Stephanie M Karle; Johannes P Haas; Franzisco E Anacleto; Michael Schultheiss; Isabella Zalewski; Anita Imm; Eva-Maria Ruf; Bettina Mucha; Arvind Bagga; Thomas Neuhaus; Arno Fuchshuber; Aysin Bakkaloglu; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

10.  Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.

Authors:  Marcin Adamczak; Marie-Luise Gross; Jan Krtil; Andreas Koch; Karin Tyralla; Kerstin Amann; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

View more
  10 in total

Review 1.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

2.  Protective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.

Authors:  Jin Zhang; Xiaozhou Hu; Shaoting Wang; Yan Zhang; Hong Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

4.  Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis.

Authors:  Shreya Kangovi; Meredith Edwards; Stephen Woloszynek; Nandita Mitra; Harold Feldman; Bernard S Kaplan; Kevin E Meyers
Journal:  Pediatr Nephrol       Date:  2011-11-25       Impact factor: 3.714

Review 5.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

6.  Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.

Authors:  Sheila Santín; Gemma Bullich; Bárbara Tazón-Vega; Rafael García-Maset; Isabel Giménez; Irene Silva; Patricia Ruíz; José Ballarín; Roser Torra; Elisabet Ars
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 8.237

7.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

8.  Functional genetic variation in aminopeptidase A (ENPEP): lack of clear association with focal and segmental glomerulosclerosis (FSGS).

Authors:  Stephen Tonna; Savita V Dandapani; Andrea Uscinski; Gerald B Appel; Johannes S Schlöndorff; Kang Zhang; Bradley M Denker; Martin R Pollak
Journal:  Gene       Date:  2007-12-03       Impact factor: 3.688

9.  Atypical focal segmental glomerulosclerosis associated with a new PODXL nonsense variant.

Authors:  David Marx; Sophie Caillard; Jérôme Olagne; Bruno Moulin; Thierry Hannedouche; Guy Touchard; Arnaud Dupuis; Christian Gachet; Anne Molitor; Seiamak Bahram; Raphael Carapito
Journal:  Mol Genet Genomic Med       Date:  2021-03-29       Impact factor: 2.183

10.  Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis.

Authors:  Moumita Barua; Eric Shieh; Johannes Schlondorff; Giulio Genovese; Bernard S Kaplan; Martin R Pollak
Journal:  Kidney Int       Date:  2013-09-18       Impact factor: 10.612

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.